By Fineline Cube 
US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) last week presented results from the dose confirmation portion of the Phase II/III waveLINE-003 study for its antibody-drug conjugate (ADC) zilovertamab vedotin at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluates the safety and efficacy of zilovertamab vedotin in combination with standard of care rituximab and gemcitabine-oxaliplatin (R-GemOx) for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after one or more lines of therapy.
Promising Clinical Results
The pre-set analysis results showed that zilovertamab vedotin administered at 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with eight complete responses (CR) and one partial response (PR). These findings highlight the potential of zilovertamab vedotin to address the significant unmet needs in DLBCL treatment.
Zilovertamab Vedotin: Targeting B-cell Malignancies
Zilovertamab vedotin is an ADC targeting ROR1, currently being investigated in multiple clinical studies. The drug aims to provide new therapeutic options for patients with B-cell malignancies, particularly those with relapsed or refractory DLBCL.-Fineline Info & Tech